Kestra Medical Technologies, LTD

Kestra Medical Technologies, Ltd. announced a new $200 million senior secured term loan facility, alongside reporting strong Q4 and FY26 financial results with significant revenue and gross margin growth.

Kestra Medical Technologies announced robust third-quarter fiscal 2026 financial results, exceeding revenue guidance and expanding gross margins.

Kestra Medical Technologies announced robust second-quarter fiscal 2026 financial results, featuring significant revenue growth and expanded gross margins, alongside an upward revision of its full-year revenue guidance.

Kestra Medical Technologies, Ltd. successfully closed an underwritten public offering, raising approximately $148.4 million in net proceeds through the sale of 6.9 million common shares at $23.00 each.

Kestra Medical Technologies announced preliminary second quarter fiscal 2026 results, projecting over 50% revenue growth and improved gross margins.

Kestra Medical Technologies announced primary results from its ACE-PAS study, confirming the strong safety and 100% effectiveness of its ASSURE Wearable Cardioverter Defibrillator.

Kestra Medical Technologies announced significant revenue and gross profit increases in its latest quarterly report, driven by patient growth, while also reporting continued net losses and ongoing efforts to address internal control weaknesses.

Kestra Medical Technologies, Ltd. reported a 53% revenue increase for the quarter ended October 31, 2025, driven by patient growth, but also saw a significant rise in net loss and identified material weaknesses in internal controls.

Kestra Medical Technologies, Ltd. announced a 52% revenue increase to $19.4 million for Q1 2026, driven by patient growth, despite a 27% rise in net loss to $25.8 million and identified material weaknesses in internal controls.

Kestra Medical Technologies reports a significant increase in revenue for the quarter ended January 31, 2025, but also discloses material weaknesses in its internal control over financial reporting.

Kestra Medical Technologies, Ltd. announced a 59% increase in revenue for the fiscal year ended April 30, 2026, driven by a significant rise in patient adoption of its ASSURE WCD.

Kestra Medical Technologies, a commercial-stage medical device company, announced a significant 115% surge in revenue for the fiscal year ended April 30, 2025, driven by strong adoption of its ASSURE WCD, despite reporting increased net losses as it continues to invest heavily in growth and infrastructure.

Timothy P. Moran, Chief Business Officer of Kestra Medical Technologies, Ltd., sold 15,256 shares of common stock on July 30, 2026.

Alfred J Ford Jr, Chief Commercial Officer of Kestra Medical Technologies, Ltd., sold 27,632 shares of common stock on July 30, 2026.

Vaseem Mahboob, Chief Financial Officer of Kestra Medical Technologies, Ltd., sold 18,188 shares of common stock on July 30, 2026.

Traci S Umberger, See Remarks and a Director of Kestra Medical Technologies, Ltd., sold 22,229 shares of common stock on July 30, 2026.

Brian Daniel Webster, See Remarks and a Director of Kestra Medical Technologies, Ltd., sold 29,822 shares of common stock on July 30, 2026.

Timothy P. Moran, Chief Business Officer of Kestra Medical Technologies, Ltd., received 39,113 shares of common stock on July 15, 2026.

Kestra Medical Technologies, Ltd. is holding its 2026 Annual General Meeting of Shareholders virtually on September 9, 2026, to elect directors and ratify auditor appointment.

Kestra Medical Technologies, Ltd. has announced its 2025 Annual Meeting of Shareholders for September 3, 2025, to vote on director elections, auditor ratification, and an employee stock purchase plan.

Kestra Medical Technologies, Ltd. announced its 2025 Annual General Meeting of Shareholders to be held virtually on September 3, 2025, to vote on director elections, auditor ratification, and a new employee stock purchase plan.

Kestra Medical Technologies, Ltd. filed an S-1MEF to register an additional 575,000 common shares, including 75,000 for underwriters' option, for its public offering.

Kestra Medical Technologies is launching a public offering of 5.5 million common shares to fund growth, reporting significant revenue increases and validating its ASSURE WCD's clinical benefits.

Kestra Medical Technologies seeks to register an additional 2,164,704 common shares, including those under the underwriters' option, following the effectiveness of its initial registration statement.

Kestra Medical Technologies files an amendment to its S-1 registration statement and announces the hiring of Al Ford as Chief Commercial Officer with a $500,000 base salary and significant equity grants.

Kestra Medical Technologies, a wearable medical device company, is seeking to raise capital through an initial public offering of 10 million common shares, with an expected price range of $14 to $16 per share.

Kestra Medical Technologies, a wearable medical device company, has filed an S-1 registration statement for an initial public offering (IPO) to further commercialize its Cardiac Recovery System platform and ASSURE WCD.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.2% of Kestra Medical Technologies' common stock as of March 31, 2026.

T. Rowe Price Associates, Inc. has reported a 7.5% beneficial ownership stake in Kestra Medical Technologies common stock.

FMR LLC and Abigail P. Johnson have disclosed an aggregate beneficial ownership of 10.2% of Kestra Medical Technologies Inc.'s common stock as of September 30, 2025.

Bain Charger Holdings, L.P., an affiliate of Bain Capital, has disclosed a beneficial ownership of 52.6% in Kestra Medical Technologies, Ltd., primarily through shared voting and dispositive power.

Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited have collectively reported a beneficial ownership of 5.2% in Kestra Medical Technologies, Ltd.'s common shares.

FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a combined beneficial ownership of 6.3% of Kestra Medical Technologies Inc.'s common stock as of March 31, 2025.